Top 10 Colorectal cancer treatment startups
Dec 28, 2024 | By Jason Kwon | 21 |
These startups develop new colorectal cancer treatments and diagnostics technologies, such as robot-assisted surgery, targeted therapy, immunotherapy, radiofrequency ablation, stereotactic body radiation therapy, cryotherapy, photodynamic therapy.
1
Country: USA | Funding: $2.8B
Exact Sciences is the developer and manufacturer of Cologuard, a non-invasive screening test for the early detection of colorectal cancer.
Exact Sciences is the developer and manufacturer of Cologuard, a non-invasive screening test for the early detection of colorectal cancer.
2
Country: USA | Funding: $1.4B
Freenome is a platform that helps design healthy conditions for an individual based on his/her cell-free genome. It employs Artificial Intelligence to detect colorectal cancer.
Freenome is a platform that helps design healthy conditions for an individual based on his/her cell-free genome. It employs Artificial Intelligence to detect colorectal cancer.
3
Country: USA | Funding: $210.1M
OncoMed Pharmaceuticals is a biotechnology company developing novel therapeutics for the treatment of cancer.
OncoMed Pharmaceuticals is a biotechnology company developing novel therapeutics for the treatment of cancer.
4
Country: USA | Funding: $206.5M
Medrobotics Corporation is a medical robotics company developing and commercializing the Flex Robotic System that gives physicians the ability to access anatomical locations that were previously difficult or impossible to reach minimally invasively.
Medrobotics Corporation is a medical robotics company developing and commercializing the Flex Robotic System that gives physicians the ability to access anatomical locations that were previously difficult or impossible to reach minimally invasively.
5
Country: USA | Funding: $156M
With a passion for pioneering breakthrough solutions, we are committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity. Acquired by Gilead Sciences
With a passion for pioneering breakthrough solutions, we are committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity. Acquired by Gilead Sciences
6
Country: USA | Funding: $106M
Totus Medicines is a provider of chemical biology technologies by creating life-changing covalent drugs.
Totus Medicines is a provider of chemical biology technologies by creating life-changing covalent drugs.
7
Country: Israel | Funding: $72M
Ayala Pharmaceuticals develops a personalized treatment for cancer.
Ayala Pharmaceuticals develops a personalized treatment for cancer.
8
Country: USA | Funding: $40M
Belong is the world’s largest social network for cancer patients and caregivers. The Belong app provides people with cancer and their families a unique and innovative personalized solution to help manage and fight cancer more effectively.
Belong is the world’s largest social network for cancer patients and caregivers. The Belong app provides people with cancer and their families a unique and innovative personalized solution to help manage and fight cancer more effectively.
9
Country: USA | Funding: $11.4M
CaroGen Corporation is an immunotherapy company employing a virus-like vesicle (VLV) platform technology. CaroGen develops vaccine candidates targeting hepatitis B and C, and other viral agents.
CaroGen Corporation is an immunotherapy company employing a virus-like vesicle (VLV) platform technology. CaroGen develops vaccine candidates targeting hepatitis B and C, and other viral agents.
10
Country: USA | Funding: $8.3M
DNAlite Therapeutics committed to bringing the next-generation of drugs to organs protected by mucus barriers. Diseases such as FAP, colorectal cancer, and Crohn's disease are currently treated with complete or partial removal of the colon and/or rectum. Our aim is to prevent, rather than manage the progression of these diseases.
DNAlite Therapeutics committed to bringing the next-generation of drugs to organs protected by mucus barriers. Diseases such as FAP, colorectal cancer, and Crohn's disease are currently treated with complete or partial removal of the colon and/or rectum. Our aim is to prevent, rather than manage the progression of these diseases.